ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

41.40
0.00
( 0.00% )
Updated: 00:17:09
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.40
Bid
41.00
Offer
42.00
Volume
552
41.40 Day's Range 42.20
0.00 52 Week Range 0.00
Previous Close
41.40
Open
41.80
Last Trade
147
@
41.4
Last Trade Time
00:03:46
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
2.29 €
(181.33%)
185.67k
UQ1Uniqure NV
14.315 €
(107.04%)
913
KH6NewAmsterdam Pharma Company NV
27.80 €
(57.95%)
101
XE7CCardiff Oncology Inc
3.485 €
(50.87%)
68.41k
1UR1Bee Vectoring Technologies International Inc
0.008 €
(45.45%)
80.16k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
3RITurmalina Metals Corp
0.0102 €
(-53.21%)
300
PA8Paion AG
0.0132 €
(-45.90%)
784
UH7ATennant Minerals NL
0.0055 €
(-26.67%)
20k
N790Blackbird Critical Metals Corp
0.0115 €
(-25.81%)
4k
AXIAtos SE
0.0024 €
(-11.11%)
393.64M
D7GNel ASA
0.2711 €
(0.44%)
2.55M
PF8European Lithium Limited
0.024 €
(-10.45%)
1.73M
3CPXiaomi Corporation
3.8255 €
(-1.78%)
1.26M
24YBrainchip Holdings Ltd
0.1566 €
(13.64%)
709.14k

Discussion

View Full Feed
georgie18 georgie18 2 minutes ago
CPIX...$3.07...🥳...Off my $2.15 Alert...

georgie18

Member Level
Re: georgie18 post# 97

Tuesday, December 10, 2024 8:12:33 AM

Post#
102
of 102
CPIX...$2.71...🥳...Off my $2.15 Alert...
CPIX
Money hunt Money hunt 2 minutes ago
ELAB The next DRUG bounce dudes!!!
ELAB
GoldDog83 GoldDog83 2 minutes ago
Another nod from Forbes.. Awareness is growing. 
The Renewable Energy Revolution In The Automotive Industry https://www.forbes.com/sites/adamsarhan/2024/12/10/the-renewable-energy-revolution-in-the-automotive-industry/
WKSP
panman2013 panman2013 2 minutes ago
Frank has NEVER paid a promised dividend with ANY of his scam companies. This one is no different. I challenge anyone to prove that statement wrong.
CNRC
Invest-in-America Invest-in-America 2 minutes ago
DATS: And yet another PR about it just minutes ago.
https://finance.yahoo.com/news/datchat-awarded-u-patent-blockchain-130700959.html
DATS
thecrusher2011 thecrusher2011 2 minutes ago
I think some of our suppositions about this guy were wrong from the start. I think he's the guy that thinks he wrote the most genius manifesto ever, keep in mind he was a valedictorian of his class.... It's pretty obvious he wanted to be caught and then he wanted everyone to see his thoughts in that
Nrdc92 Nrdc92 3 minutes ago
Lebby is certainly not a "liar;" however, his proclamations are based on his strong personal convictions, which seem to be chronically misaligned with the expectations/demands of customers and the broader market; hence, the disconnect between rhetoric and reality. 
LWLG
georgie18 georgie18 3 minutes ago
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie
CMRX
georgie18 georgie18 3 minutes ago
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie
CMRX
diamondguru-one diamondguru-one 3 minutes ago
99,999,999 each
GNCP
GrandAdmiralThrawn GrandAdmiralThrawn 3 minutes ago
Who the heck is BF
HMBL
georgie18 georgie18 3 minutes ago
CMRX...$2.37...🥳...Off my $2.02 Alert...

georgie18

Member Level
Re: georgie18 post# 667332

Monday, December 09, 2024 4:23:42 PM

Post#
667335
of 667357
CMRX...$2.22...🥳...

georgie
CMRX
Dragonman1 Dragonman1 4 minutes ago
hey what happened to Varmit?
GNCP
KVM KVM 4 minutes ago
Seems to be their modus operandi.
VERI
georgie18 georgie18 5 minutes ago
CPIX...$2.71...🥳...Off my $2.15 Alert...

georgie18

Member Level
Re: georgie18 post# 667334

Monday, December 09, 2024 4:26:19 PM

Post#
667337
of 667357
CPIX...$2.27...🥳

georgie18
CPIX
resx18 resx18 5 minutes ago
Encased in a diamond, which is one of the hardest materials known, the battery safely captures radiation to produce power.
KNOS
tedpeele tedpeele 5 minutes ago
A year ago reliability testing results were going to blow the socks off the industry.

Remember?

Yet here we are. I’m not even gonna ask the most obvious question I think even the lowest of low information group here knows what it is.
LWLG
Dragonman1 Dragonman1 6 minutes ago
Hopefully Today we see some more Volume! I read somewhere the 700 million that was traded were 11 different trades in total.
GNCP
surfkast surfkast 6 minutes ago
OMG! The kiss of death for sure.
HMBL
cottonmather cottonmather 6 minutes ago
Tidbits: BLM leaders are calling for vigilanteism immediately in US. Milk is near shortage levels - maybe a couple weeks. Taiwan is suurounded by the Chinese Navy. Israel Army has entered deep into Syria - 20km from Damascus. Cocoa/chocolate is about gone in the US. Egg inventories are about go
georgie18 georgie18 6 minutes ago
CPIX...$2.71...🥳...Off my $2.15 Alert...

georgie18

Member Level
Re: georgie18 post# 667334

Monday, December 09, 2024 4:26:19 PM

Post#
667337
of 667357
CPIX...$2.27...🥳

georgie18
CPIX
getmoreshares getmoreshares 6 minutes ago
still limited............... SMH
CGAC
budfoxfun budfoxfun 6 minutes ago
Collaboration of media with QVC and HSN (Home Shopping Network) with the support of Mann Media and Worldwide TV Products has the potential to generate millions of dollars in revenue, further reinforcing SGTM's commitment to sustainable growth.
SGTM
trader_ron trader_ron 6 minutes ago
$AIDM 🔥 Must-Listen Alert! 🔥 Dive into research with @WTR_Research! 🎙️ This podcast discuss #Veldona's therapeutic potential and ongoing clinical trials in Taiwan, covering HIV+ oral warts, #Sjogren’s Syndrome, and cat FCGS. Don't miss out!
⏳ #AinosInc $AIMD $AIMDW #na
AIDM AIMD AIMDW

Your Recent History

Delayed Upgrade Clock